Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.

Drugmakers see a pricing blueprint in an $850,000 gene therapy
Read More

Bagikan Berita Ini

Search

Drugmakers see a pricing blueprint in an $850,000 gene therapy

0 Response to "Drugmakers see a pricing blueprint in an $850,000 gene therapy"

Posting Komentar

Drugmakers see a pricing blueprint in an $850,000 gene therapy

Related Posts :

0 Response to "Drugmakers see a pricing blueprint in an $850,000 gene therapy"

Posting Komentar